WuXi AppTec Ranked #1 in Global Life Sciences Tools & Services Industry in 2024 S&P Global Corporate Sustainability Assessment
SHANGHAI, Nov. 11, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has been ranked #1 in the global Life Sciences Tools & Services sector in the 2024 S&P Glo...
WuXi AppTec Named Global CRDMO Company of the Year by Frost & Sullivan for the Eighth Consecutive Year
SHANGHAI, Oct. 29, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has been awarded the 2024 Global CRDMO Company of the Year Award by Frost & Sullivan, a gr...
Despite External Challenges, WuXi AppTec Revenue and Profit Continued to Grow QoQ in the First Three Quarters of 2024; the Third Quarter Revenue Back to RMB 10+ Billion, Up 14.6% YoY Excluding COVID-19 Commercial Projects; Backlog Up 35.2% YoY
* Revenue Reached RMB10,461 Million in the Third Quarter, Excluding COVID-19 Commercial Projects, Up 14.6% Year-over-Year * Revenue Reached RMB27,702 Million for the First Three Quarters, Excluding COVID-19 Commercial Projects, Up 4.6% Year-over-Year * Net Profit Attributable to the Owners o...
Despite External Challenges, WuXi AppTec Maintained Stable Operations in First Half of 2024; Revenue and Profit of the Second Quarter Both Steadily Improved QoQ as Expected, with Revenue Up 16.0% QoQ and Adjusted Non-IFRS Net Profit Up 28.5% QoQ
* Revenue Reached RMB9,259 Million in the Second Quarter, Excluding COVID-19 Commercial Projects, Up 0.3% Year-over-Year * Revenue Reached RMB17,241 Million for the First Half, Excluding COVID-19 Commercial Projects, Down 0.7% Year-over-Year * Net Profit Attributable to the Owners of the Com...
WuXi AppTec Achieved First Quarter 2024 Target Despite External Challenges, Maintaining Stable Operations
* Revenue Reached RMB7,982 Million; Excluding COVID-19 Commercial Projects, Down 1.8% * Net Profit Attributable to the Owners of the Company Reached RMB1,942 Million; Diluted Earnings per Share (EPS) Reached RMB0.66 * Adjusted Non-IFRS Net Profit Attributable to the Owners of the Company Re...
WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time
* Revenue Up 2.5% Year-over-Year to RMB40,341 Million; Excluding COVID-19 Commercial Projects, Up 25.6% * Net Profit Attributable to the Owners of the Company[1] Increased 9.0% to RMB9,607 Million; Diluted Earnings per Share (EPS) Increased 14.9% to RMB3.24 * Adjusted Non-IFRS Net Profit Att...
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma
AMTAGVI is the first and only one-time, individualized T cell therapy to receive U.S. FDA approval fora solid tumor cancer. PHILADELPHIA, Feb. 20, 2024 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced that the U.S. Food and Drug Admini...
WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site
Expansion Boosts Solid-Phase Peptide Synthesis Total Reactor Volume to 32,000 Liters in Response to Surging Demand SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, b...
WuXi AppTec Named 2023 Global Contract Research, Development and Manufacturing Organization Company of the Year by Frost & Sullivan
SHANGHAI, Nov. 8, 2023 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, recei...
WuXi AppTec Continued Solid Growth in the First Three Quarters of 2023 on Top of an Exceptionally Strong Year in 2022, with Profit Growth Continuously Exceeding Revenue Growth
* Revenue of RMB10,670 Million in the Third Quarter, Single Quarter Revenue Back to overRMB10 Billion; Revenue of RMB29,541 Million in the First Three Quarters, Up 4.0% Year-over-Year; Excluding COVID-19 Commercial Projects, Up 23.4% * Net Profit Attributable to Owners of the Company for the ...
WuXi AppTec Announced Strong Results of the Second Quarter and First Half of 2023, on Top of an Exceptionally Strong Year in 2022
* Revenue of RMB9,908 Million in the Second Quarter, Up 6.7% Year-over-Year; Excluding COVID-19 Commercial Projects, Up 39.5% * Revenue of RMB18,871 Million in the First Half, Up 6.3% Year-over-Year; Excluding COVID-19 Commercial Projects, Up 27.9% * Net Profit Attributable to Owners of the Co...
WuXi AppTec Continued Solid Growth in First-Quarter of 2023 On Top of an Exceptionally Strong Year of 2022
Revenue Up 5.8% Year-Over-Year to RMB8,964 Million Net Profit Attributable to Owners of the Company Up 32.0% Year-Over-Year to RMB2,168 Million Diluted Earnings per Share (EPS) Up 35.8% Year-Over-Year to RMB0.72 Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 14.1% Year-Over-...
WuXi AppTec Reports Record Year-to-Date Results in 2022, Third Quarter Revenue over RMB10 Billion
Revenue Up 71.9% Year-Over-Year to RMB28,395 Million Net Profit Attributable to Owners of the Company Up 107.1% Year-Over-Year to RMB7,378 Million Diluted Earnings Per Share (EPS) Up 90.1% Year-Over-Year to RMB2.30 Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 77.9% Year...
WuXi ATU Announces Licensing Agreement with Janssen for TESSA™ Technology
PHILADELPHIA, Aug. 11, 2022 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced a licensing agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson ("Janssen"). Under this agreement, WuXi ATU ...
WuXi AppTec Reports Record First-Quarter In 2022
Revenue Up 71.2% Year-Over-Year to RMB8,474 Million Net Profit Attributable to Owners of the Company Up 9.5% Year-Over-Year to RMB1,643 Million Diluted Earnings Per Share (EPS) Up 3.9% Year-Over-Year to RMB0.53 Adjusted Non-IFRS[1] Net Profit Attributable to Owners of the Company Up 85.8% Ye...
Statement by WuXi AppTec Regarding Recent Market Fluctuation
SHANGHAI, Dec. 15, 2021 /PRNewswire/ -- Our company's activities continue apace and we remain confident in our platform, which enables our global customers and serves patients around the world. We will provide any new information as warranted and in compliance with applicable laws and regulations...
WuXi AppTec Receives 2021 Global Customer Value Leadership Award from Frost & Sullivan
SHANGHAI, Dec. 8, 2021 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, announced that it is a recipient of the 2021 Global CRDMO Customer Value Leadership Award from Frost & Sullivan, a global ...
WuXi AppTec Receives AA ESG Rating from MSCI
SHANGHAI, Sept. 5, 2021 /PRNewswire/ -- WuXi AppTec ("the Company") is pleased to announce that Morgan Stanley Capital International ("MSCI") has upgraded its MSCI ESG Rating to AA. The Company also received outstanding scores in the areas of "corporate governance" and "product safety and quality...
WuXi AppTec Reports Strong 2021 Interim Results
* Revenue Up 45.7% Year-Over-Year to RMB10,537 Million * Net Profit Attributable to Owners of the Company Up 55.8% Year-Over-Year to RMB2,675 Million * Diluted EPS Up 46.8% Year-Over-Year to RMB0.91 * Adjusted Non-IFRS[1] Net Profit Attributable to Owners of the Company Up 67.8% Year-Over-...
WuXi AppTec Reports Strong 2020 Annual Results
Revenue Up 28.5% Year-over-Year to RMB16,535 Million Net Profit Attributable to Owners of the Company Up 59.6% Year-over-Year to RMB2,960 Million Diluted EPS Up 56.3% Year-over-Year to RMB1.25 Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 48.1% Year-over-Year toRMB3,565 Mil...
